This unique mechanism makes PCSK9 inhibitors a valuable addition to the treatment arsenal for managing dyslipidemia, especially in patients who have not reached target LDL-C levels with standard therapies (7). The gene discussed is PCSK9; the disease is metabolic syndrome.